Henry Ford Health

Henry Ford Health Scholarly Commons
Infectious Diseases Articles

Infectious Diseases

9-12-2021

Changing trends in mortality among solid organ transplant
recipients hospitalized for COVID-19 during the course of the
pandemic
Madeleine R. Heldman
Olivia S. Kates
Kassem Safa
Camille N. Kotton
Sarah J. Georgia

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/
infectiousdiseases_articles

Recommended Citation
Heldman MR, Kates OS, Safa K, Kotton CN, Georgia SJ, Steinbrink JM, Alexander BD, Hemmersbach-Miller
M, Blumberg EA, Multani A, Haydel B, La Hoz RM, Moni L, Condor Y, Flores S, Munoz CG, Guitierrez J, Diaz
EI, Diaz D, Vianna R, Guerra G, Loebe M, Rakita RM, Malinis M, Azar MM, Hemmige V, McCort ME,
Chaudhry ZS, Singh PP, Hughes Kramer K, Velioglu A, Yabu JM, Morillis JA, Mehta SA, Tanna SD, Ison MG,
Derenge AC, van Duin D, Maximin A, Gilbert C, Goldman JD, Lease ED, Fisher CE, and Limaye AP. Changing
Trends in Mortality Among Solid Organ Transplant Recipients Hospitalized for Covid-19 During the Course
of the Pandemic. Am J Transplant 2021.

This Article is brought to you for free and open access by the Infectious Diseases at Henry Ford Health Scholarly
Commons. It has been accepted for inclusion in Infectious Diseases Articles by an authorized administrator of
Henry Ford Health Scholarly Commons.

Authors
Madeleine R. Heldman, Olivia S. Kates, Kassem Safa, Camille N. Kotton, Sarah J. Georgia, Julie M.
Steinbrink, Barbara D. Alexander, Marion Hemmersbach-Miller, Emily A. Blumberg, Ashrit Multani, Brandy
Haydel, Ricardo M. La Hoz, Lisset Moni, Yesabeli Condor, Sandra Flores, Carlos G. Munoz, Juan Guitierrez,
Esther I. Diaz, Daniela Diaz, Rodrigo Vianna, Giselle Guerra, Matthias Loebe, Robert M. Rakita, Maricar
Malinis, Marwan M. Azar, Vagish Hemmige, Margaret E. McCort, Zohra S. Chaudhry, Pooja P. Singh, Kailey
Hughes Kramer, Arzu Velioglu, Julie M. Yabu, Jose A. Morillis, Sapna A. Mehta, Sajal D. Tanna, Michael G.
Ison, Ariella C. Derenge, David van Duin, Adrienne Maximin, Carlene Gilbert, Jason D. Goldman, Erika D.
Lease, Cynthia E. Fisher, and Ajit P. Limaye

This article is available at Henry Ford Health Scholarly Commons: https://scholarlycommons.henryford.com/
infectiousdiseases_articles/159

Received: 27 May 2021

|

Revised: 31 August 2021

|

Accepted: 7 September 2021

DOI: 10.1111/ajt.16840

AJT

B R I E F C O M M U N I C AT I O N

Changing trends in mortality among solid organ transplant
recipients hospitalized for COVID-19 during the course of the
pandemic
Madeleine R. Heldman1
| Olivia S. Kates1
| Kassem Safa2
| Camille N. Kotton2 |
Sarah J. Georgia2 | Julie M. Steinbrink3 | Barbara D. Alexander3 |
Marion Hemmersbach-Miller4
| Emily A. Blumberg5
| Ashrit Multani6 |
Brandy Haydel7 | Ricardo M. La Hoz8
| Lisset Moni9 | Yesabeli Condor9 |
Sandra Flores9 | Carlos G. Munoz9 | Juan Guitierrez9 | Esther I. Diaz9 | Daniela Diaz9 |
Rodrigo Vianna9 | Giselle Guerra9
| Matthias Loebe9 | Robert M. Rakita1
|
10
10
11
Maricar Malinis
| Marwan M. Azar
| Vagish Hemmige | Margaret E. McCort11 |
Zohra S. Chaudhry12
| Pooja P. Singh13 | Kailey Hughes Kramer14 | Arzu Velioglu15
|
16
17
18
19
Julie M. Yabu
| Jose A. Morillis
| Sapna A. Mehta
| Sajal D. Tanna
|
19
20
21
Michael G. Ison
| Ariella C. Derenge
| David van Duin
| Adrienne Maximin22 |
Carlene Gilbert23 | Jason D. Goldman1,24
| Erika D. Lease25
| Cynthia E. Fisher1 |
Ajit P. Limaye1 | on behalf of the UW COVID-19 SOT Study Team*
1

Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington

2

Massachusetts General Hospital, Boston, Massachusetts

3

Division of Infectious Diseases, Department of Medicine, Duke University, Durham, North Carolina

4

Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas

5

Department of Medicine, Division of Infectious Diseases, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania

6

Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California

7

Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York

8

Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, Texas

9

University of Miami/Jackson Memorial Hospital, Miami, Florida

10

Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut

11

Division of Infectious Disease, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York

12

Transplantation Infectious Diseases and Immunotherapy, Henry Ford Health System, Detroit, Michigan

13

Division of Nephrology, University of New Mexico, Albuquerque, New Mexico

14

Transplant Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania

15

Department of Internal Medicine, Division of Nephrology, School of Medicine, Marmara University, Istanbul, Turkey

16

Division of Nephrology, Department of Medicine, University of California, Los Angeles, California

17

Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio

18

NYU Langone Transplant Institute, New York, New York

Abbreviations: BMI, body mass index; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; ICU, intensive care unit; mTOR, mammalian target of rapamycin; SARS-CoV-2 ,
severe acute respiratory syndrome coronavirus 2; SOTR, solid organ transplant recipients.
Cynthia E. Fisher and Ajit P. Limaye contributed equally to this work.
*The members of the UW COVID-19 SOT Study Team are provided in the Acknowledgment section.

© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.
Am J Transplant. 2021;00:1–10.	

amjtransplant.com

|

1

|

2
19

HELDMAN et al.

AJT

Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois

20

Department of Medicine, Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, Pennsylvania

21

Division of Infectious Diseases, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina

22

INTEGRIS Health, Oklahoma City, Oklahoma

23

Banner Health, Phoenix, Arizona

24

Swedish Medical Center, Seattle, Washington

25

Division of Pulmonology, Critical Care, and Sleep Medicine, University of Washington, Seattle, Washington

Correspondence
Madeleine R. Heldman, MD, University
of Washington Medical Center, Seattle,
WA, USA.
Email: mrh157@uw.edu
Funding information
This work was supported by the National
Institute of Allergy and Infectious
Diseases (T32AI118690 to M.R.H. and
O.S.K.) and the National Heart, Lung, and
Blood Institute (HL143050 to C.E.F.) at the
National Institutes of Health. The content
is solely the responsibility of the authors
and does not necessarily represent the
official views of the National Institutes of
Health.

Mortality among patients hospitalized for COVID-19 has declined over the course
of the pandemic. Mortality trends specifically in solid organ transplant recipients
(SOTR) are unknown. Using data from a multicenter registry of SOTR hospitalized for
COVID-19, we compared 28-day mortality between early 2020 (March 1, 2020–June
19, 2020) and late 2020 (June 20, 2020–December 31, 2020). Multivariable logistic
regression was used to assess comorbidity-adjusted mortality. Time period of diagnosis was available for 1435/1616 (88.8%) SOTR and 971/1435 (67.7%) were hospitalized: 571/753 (75.8%) in early 2020 and 402/682 (58.9%) in late 2020 (p < .001).
Crude 28-day mortality decreased between the early and late periods (112/571
[19.6%] vs. 55/402 [13.7%]) and remained lower in the late period even after adjusting
for baseline comorbidities (aOR 0.67, 95% CI 0.46–0.98, p = .016). Between the early
and late periods, the use of corticosteroids (≥6 mg dexamethasone/day) and remdesivir increased (62/571 [10.9%] vs. 243/402 [61.5%], p < .001 and 50/571 [8.8%] vs.
213/402 [52.2%], p < .001, respectively), and the use of hydroxychloroquine and IL-6/
IL-6 receptor inhibitor decreased (329/571 [60.0%] vs. 4/492 [1.0%], p < .001 and
73/571 [12.8%] vs. 5/402 [1.2%], p < .001, respectively). Mortality among SOTR hospitalized for COVID-19 declined between early and late 2020, consistent with trends
reported in the general population. The mechanism(s) underlying improved survival
require further study.
KEYWORDS

clinical research/practice, infection and infectious agents -viral, infectious disease, organ
transplantation in general, quality of care/care delivery
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I NTRO D U C TI O N

between March 1 and April 15, 2020.1 This registry accrued additional cases diagnosed between April 15 and December 31, 2020.

During the early portion of 2020, short-term mortality among solid

Here, we compare outcomes by 28 days among SOTR hospitalized

organ transplant recipients (SOTR) hospitalized for COVID-19 was

for COVID-19 during the first half of 2020 to those diagnosed during

high, with estimates ranging from approximately 18%–30%.1–3

the second half of 2020, to determine whether reductions in mortal-

Multiple recent studies of hospitalized adults (general population)

ity reported among the general population have similarly occurred

with COVID-19 have reported that mortality has declined sub-

among SOTR.

stantially since the start of the pandemic in the United States and
Europe, from 20% to 25% during March and April 2020 to less than
10% during July through November 2020.4–7 The overall decline in
mortality has been attributed to various factors including earlier diagnosis due to greater access of testing, improvements in the sup-

2
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M ATE R I A L S A N D M E TH O DS

2.1 | Study design and patients

portive management, and the potential impact of therapies such as
corticosteroids and remdesivir.4 Whether similar decreases in mor-

We performed a multicenter observational cohort study of SOTR

tality have occurred in SOTR has not been reported.

with laboratory-confirmed SARS-CoV-2 infection, as described pre-

We previously described the 28-day outcomes of SOTR hospi-

viously.1 This study was approved by the institutional review board

talized for COVID-19 who were enrolled in a multicenter registry

(IRB) at the University of Washington with a waiver of informed
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consent (STUDY00009698). The University of Washington IRB is-

secondary outcomes. Age, sex, organ transplanted, geographic lo-

sued a “no human subjects research” designation for local sites con-

cation, comorbidities, and features related to immunosuppression

tributing de-identified patient data. Individual sites sought local IRB

were evaluated as potential risk factors for mortality using univari-

approval as needed.

able logistic regression (Table S2). These covariates were selected a
priori based on hypotheses and/or prior studies showing a relationship with COVID-19 mortality.10,11 A multivariable logistic regression

2.2 | Data collection

model was constructed using covariates with at least a prevalence
of 5% and a p < .2 in the univariable analysis. The final multivariable

Data were collected using an online data collection tool, REDCap
1,8

(Research Electronic Data Capture), as described previously.

model included age, receipt of lung transplant hypertension, diabe-

A

tes mellitus, heart failure, obesity, chronic kidney disease, coronary

summary of all collected variables is shown in Table S1. Only patients

artery disease, and chronic lung disease. Age was assessed as a di-

who were hospitalized within 28 days of diagnosis, and for whom

chotomous variable (age ≤ 65 years vs. >65 years) based on clini-

28-day follow-up forms were completed, were included in this analy-

cal relevance and in accordance with prior studies.5,12 Stata version

sis. Patients were excluded if they were hospitalized for another in-

16.1 (StataCorp) and R version 4.0.2 were used to perform statistical

dication prior to or concurrent with their first positive SARS-CoV-2

analyses.

test (Figure S1). For example, a patient admitted to the hospital for a
hip fracture with a positive SARS-CoV-2 screening test on admission
would have been excluded. Patient race and ethnicity were collected
as distinct variables and reported by the contributor based on observations or documentation in the electronic medical record. Race

3
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3.1 | Study population

and ethnicity were collected as part of the registry to characterize
Of 1616 SOTR with COVID-19 in 2020, the time period of diagnosis

the study population.
Contributors were instructed to submit cases of COVID-19 in

was available for 1435 patients (88.8%). Of these 1435 patients, 973

SOTR that were diagnosed between March 1 and December 31,

(67.8%) were hospitalized for COVID-19 within the 28 days follow-

2020. Because dates are considered potentially identifiable pro-

ing diagnosis: 571/753 (75.8%) during the early period and 402/682

tected health information, the month and day of COVID-19 diagno-

(58.9%) during the late period (p < .001, Figure S1). Overall, the

sis could not be reported. Instead, season of diagnosis (the Northern

baseline characteristics of hospitalized patients excluded due to an

Hemisphere's winter, spring, summer, or fall) was captured. Cases

unknown period of diagnosis were similar to those of the included

were considered to have occurred during the early period of 2020 if

population with an available time period of diagnosis (Table S3).

they were diagnosed in the winter or spring (corresponding to March

The mean age was similar in the early (57 ± 13 years) and late

1–June 19, 2020) and were considered to have occurred during the

(58 ± 14 years) periods (p = .28). The proportions of cases from

late period of 2020 if they occurred during the summer or fall (cor-

the Northeastern and Midwestern United States were higher in

responding to June 20–December 31, 2020). The time cutoff in June

the early period compared to the late period (284/571 [49.7%]

2020 was used in accordance with a mortality inflection point ob-

vs. 74/402 [18.4%], p < .001 and 97/571 [17.0%] vs. 7/402 [1.7%],

served in the general population4,5 and because it closely coincided

p < .001), and the proportions of cases from the Southern and

with two major advances for COVID-19: evidence supporting the

Western United States were lower in the early period compared

use of corticosteroids for patients requiring supplemental oxygen

to the late cohort (100/571 [17.5%] vs. 194/402 [48.3%], p < .001

and the emergency use authorization of remdesivir in the United

and 74/571 [13.0%] vs. 119/402 [29.6%], p < .001). Black patients

States.9

accounted for a higher proportion of cases in the early period than
the later period (221/523 [42.3%] vs. 113/375 [30.1%], p < .001).
Hispanic or Latinx patients accounted for a lower proportion of

2.3 | Statistical analysis

cases in the early period than in the late period (151/545 [27.7%]
vs. 142/293 [36.2%], p = .006). There was a higher proportion of

Demographic and baseline characteristics were assessed as counts

kidney recipients and a lower proportion of lung recipients in the

and percentages for categorical values and as a mean (standard de-

early cohort compared to the late cohort (383/571 [67.1%] vs.

2

225/402 [56.0%], p = .001, and 41/571 [7.2%] vs. 63/402 [15.7%],

and Fisher's exact tests were used to assess proportions of categori-

p < .001, respectively). The proportion of patients with absolute

cal variables. Continuous variables were assessed using Student's

lymphopenia on presentation increased from the early to the late

t-test or the Wilcoxon rank-sum test. Death by 28 days was the pri-

periods (150/535 [28.0%] vs. 131/365 [35.9%], p = .01). The pro-

mary outcome, and admission to the intensive care unit (ICU), use

portion with abnormal chest imaging at presentation was similar

of mechanical ventilation, initiation of renal replacement therapy,

between time periods (450/541 [83.2%] vs. 294/362 [81.2%],

pathogen-proven bacterial and fungal pneumonia, bloodstream in-

p = .45). Additional baseline characteristics of hospitalized patients

fection, acute cellular rejection, and duration of hospitalization were

in each time period are shown in Table 1.

viation) or median (interquartile range) for continuous variables. χ

1 (0.2)

57.0 (13.5)

Age > 65 year

Mean age (SD), years

74 (13.0)
16 (2.8)

International

0 (0.0)

68 (11.9)
41 (7.2)
3 (0.5)

Heart

Lung

18 (4.5)

47 (8.2)

52 (9.1)

124 (21.7)

Chronic lung disease

125 (31.1)

202 (35.4)

Chronic kidney disease

Coronary artery disease

15 (3.7)

58 (14.4)

135 (35.1)

201 (35.8)

Obesity (BMI ≥ 30 kg/m2)d

Heart failure

191 (47.5)

458 (80.2)
301 (54.3)

Diabetes mellitus

296 (73.6)

52 (12.9)

Hypertension

Underlying comorbidities

Other

63 (15.7)

76 (13.3)

62 (15.4)

383 (67.1)

Kidney

225 (56.0)

8 (2.0)

119 (29.6)

194 (48.3)

7 (1.7)

74 (18.4)

57.6 (14.1)

135 (33.6)

142 (36.2)

231 (61.6)

3 (0.8)

10 (2.7)

113 (30.1)

18 (4.8)

244 (60.9)

Late period (n = 402)

Liver

Organc

100 (17.5)

Southern U.S.

97 (17.0)

Western U.S.

284 (49.7)

Northeastern U.S.

Midwestern U.S.

Geographic location

151 (27.7)
167 (29.3)

Hispanic or Latinx ethnicityb

269 (51.4)

Pacific Islander

White

4 (0.8)

221 (42.3)

Black

Indigenous People

28 (5.4)

Asian

Race

366 (64.1)

Male

a

Early period (n = 571)

AJT

(Continues)

.001

.004

.16

.81

.02

.04

.02

<.001

.63

.35

<.001

.42

<.001

<.001

<.001

<.001

.47

.15

.006

<.001

.3

p-value

|

Covariate, n (%)

TA B L E 1 Baseline characteristics and treatments among hospitalized patients by season for those with season of diagnosis available (N = 973)
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g

450 (83.2)

150 (28.0)
294 (81.2)

131 (35.9)

23 (5.7)

277 (68.9)

313 (77.8)

368 (91.5)

204 (50.8)

30 (5.3)

Late period (n = 402)

.49

.01

.94

.01

.02

.6

.41

.27

p-value

BMI was available for 561 patients in the early period and 385 patients in the early period.

Chest imaging was performed in 541 patients in the early period and 362 patients in the late period. Refers to changes from baseline for patients with abnormal chest imaging prior to COVID-19.

j

Dose of baseline corticosteroids consistent of ≤5 mg/day of prednisone or equivalent (early period, n = 414; late period, n = 267) or >5 mg/day of prednisone (early period, n = 24; late period, n = 10).

Absolute lymphocyte count was measured in 535 patients in the early period and 365 patients in the late period.

i

h

Includes mycophenolate mofetil, mycophenolic acid, azathioprine, and leflunomide.

Includes tacrolimus and cyclosporine.

g

f

Induction immunosuppression refers to polyclonal antilymphocyte globulin (early period, n = 16; late period, n = 17), alemtuzumab (early period, n = 2; late period, n = 0), basiliximab (early period, n = 9;
late period, n = 6), pulse steroids at ≥500 mg methylprednisolon e/day for ≥3 days (early period, n = 6; late period, n = 14), rituximab (early period, n = 1; late period, n = 2), and plasmapheresis (early period,
n = 0; late period, n = 1). Some patients received more than one induction agent.

e

d

Kidney includes 16 kidney/pancreas recipients. Liver includes 28 liver/kidney and 1 liver/pancreas/small bowel recipients. Heart includes 13 heart kidney and 1 heart/kidney/small bowel recipients. Lung
includes 2 heart/lung, 1 liver/lung, and 1 lung/kidney/islet cell recipients. Other organ recipients include 2 small bowel recipients and 1 vascular composite allograft recipient.

c

Ethnicity was available for 545 patients in the early period and 293 patients in the late period.

Race was available for 523 patients in the early period and 375 patients in the late period.

b

a

Abbreviations: ALC, absolute lymphocyte count; BMI, body mass index; CNI, calcineurin inhibitor, mTOR, mammalian target of rapamycin; SD, standard deviation, U.S., United States.

Abnormal chest imaging

i

Lymphopenia (ALC < 0.5 × 109/L)h

Presenting features

Any mTOR inhibitor

32 (5.6)

438 (76.7)

Any antimetabolitef

Any corticosteroid

528 (92.5)
406 (71.1)

Any CNIf

305 (53.4)

28 (7.0)

Early period (n = 571)

CNI, antimetabolite, corticosteroids

Induction in the past 3 monthse

Baseline immunosuppression

Covariate, n (%)

TA B L E 1 (Continued)
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3.2 | Outcomes by 28 days during study periods

equivalent to ≥6 mg dexamethasone/day) and remdesivir increased
between the early and late periods (62/571 [10.9%] vs. 243/402

Among SOTR hospitalized for COVID-19, crude mortality by 28 days

[61.4%], p < .001, and 50/571 [8.8%] vs. 213/402 [53.0%], p < .001,

declined between the early and late periods (112/571 [19.6%] vs.

respectively). Twenty patients in the early period and four patients in

55/402 [13.7%], respectively, p = .016). Unadjusted survival curves are

the late period received both corticosteroids and anti-IL6/IL-6R mono-

shown in Figure 1. After adjusting for differences in baseline comor-

clonal antibody. Three hospitalized patients in the late period received

bidities between time periods, the odds of death remained lower in

a monoclonal antibody targeting the SARS-CoV-2 spike protein dur-

the late period (aOR 0.67, 95% CI 0.46–0.98, p = .04). The proportion

ing their clinical course; no patients in the early period were treated

of patients admitted to the ICU was similar in early and late periods

with anti-SARS-CoV-2 monoclonal antibodies. In both the early and

(213/551 [38.6%] vs. 152/388 [39.2%], p = .87, respectively). The pro-

late periods, immunosuppression was reduced in over 70% of patients

portion of patients who required any form of supplemental oxygen

(Table 3). In patients taking antimetabolites at the time of COVID-19

increased between the early and late periods (395/571 [71.0%] vs.

diagnosis, cessation of the antimetabolite was common in both the

303/394 [76.9%], p = .04, respectively), but the use of mechanical ven-

early and late periods (270/406 [66.5%] vs. 206/313 [66.5%], respec-

tilation declined between the early and late periods (171/554 [30.9%]

tively, p = .87). In patients taking calcineurin inhibitors at the time of

vs. 93/394 [23.6%], p = .014, respectively). Initiation of renal replace-

COVID-19 diagnosis, reduction of target calcineurin troughs was more

ment therapy among patients who did not require dialysis prior to ad-

common in the early period compared to the late period (160/571

mission declined between the early and late periods (89/528 [17.8%]

[30.3%] vs. 49/402 [13.3%], respectively, p < .001).

vs. 48/402 [12.9%], p = .051). The median length of hospitalization was
similar in the early and late periods (10 days [IQR: 5–19] and 8 days
[IQR: 5–18], p = .08, respectively). The proportion of patients who de-

4
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DISCUSSION

veloped bacterial pneumonia, bloodstream infections, and acute cellular rejection were similar between the two time periods (Table 2).

In this large multicenter observational cohort study, mortality
among SOTR hospitalized for COVID-19 declined during the pan-

3.3 | Therapeutic interventions used during
study periods

demic, even when controlled for baseline comorbidities, similar to
trends reported in the general population.
We explored potential explanations for the observed reduction
in mortality during the most recent study period. We noted key dif-

The use of hydroxychloroquine and monoclonal antibodies targeting

ferences in patient characteristics between the study periods: the

interleukin 6 (IL-6) or the IL-6-receptor (IL-6R) declined between the

prevalence of heart and lung disease, high-risk comorbidities that

early and late periods (Table 3). The use of corticosteroids (at a dose

are strongly associated with mortality in SOTR with COVID-19,1 was
significantly lower in the late, more recent period. However, mortality remained lower in the late period after adjusting for these
confounding conditions, consistent with findings from the general
population demonstrating decreased mortality among persons of
all ages and in those with multiple medical comorbidities.4,13 Thus,
differences in underlying comorbidities between study periods are
unlikely to fully explain the observed decrease in mortality and suggest that other factors were likely contributory.
We also assessed COVID-19 illness severity between time periods as a possible explanation for the observed decline in mortality.
SARS-CoV-2 testing availability increased significantly throughout
2020,14 potentially facilitating earlier detection of milder cases of
COVID-19 during the late study period. Indeed, we observed a significantly lower rate of hospitalization after diagnosis in the late
(more recent) period. To minimize the impact of potential variations
in baseline severity of illness between time periods, we limited our
analysis to hospitalized patients with the rationale that indications for
hospitalization likely remained similar between periods. Importantly,
surrogate markers of disease severity among hospitalized patients
included in the analysis did not vary substantially between time
periods. There was no difference in the prevalence of abnormal

F I G U R E 1 Unadjusted survival curves in solid organ transplant
recipients hospitalized for COVID-19 in early and late 2020

chest imaging or ICU admission between time periods, and absolute
lymphopenia at illness presentation was more common in the later

HELDMAN et al.
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TA B L E 2 Outcomes by 28 days in solid organ transplant recipients hospitalized for COVID-19 during early and late 2020
Early period
(n = 571)

Outcomes, n (%)

Late period
(n = 402)

Unadjusted OR
(95% CI)a

p-valuea

Adjusted OR (95% CI),
p-valueb
0.67 (0.46–0.98), p = .037

Death

112 (19.6)

55 (13.7)

0.7 (0.5–0.9)

.016*

ICU admissionc

213 (38.7)

152 (39.2)

1.0 (0.8–1.3)

.87

Any supplemental oxygend

395 (71.0)

303 (76.9)

1.4 (1.0–1.8)

.04*

167 (30.0)

152 (38.5)

1.5 (1.1–1.9)

.01*

High flow nasal cannula

43 (7.7)

49 (12.4)

1.7 (1.1–2.6)

.02*

Noninvasive positive pressure ventilation

14 (2.5)

9 (2.3)

0.9 (0.4–2.1)

.82

171 (30.9)

93 (23.6)

0.7 (0.5–0.9)

.014

89 (17.8)

48 (12.9)

0.7 (0.5–1.0)

.051

43 (7.5)

34 (8.5)

1.2 (0.7–1.8)

.60

Nasal cannula or simple facemask

Mechanical ventilation
New RRTe
Infection

f

Bacterial pneumonia
Fungal pneumonia
Bloodstream infection
Acute cellular rejection
Median length of hospitalization, days (IQR)

g

2 (0.4)

5 (1.3)

3.6 (0.7–18.5)

.13

37 (6.5)

28 (7.0)

1.1 (0.6–1.8)

.77

4 (0.7)

6 (1.5)

2.1 (0.6–7.7)

.29

10 (5–19)

8 (5–18)

.08

Abbreviations: CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; OR, odds ratio; RRT, renal replacement therapy.
a

Reference is early period.

b

P-values reflect χ2 and Fisher's exact tests for heterogeneity for dichotomous outcomes and Wilcoxon rank-sum test for the continuous outcome
(length of hospitalization). *Indicates statistical significance at α = .05.
c

Adjusted odds ratio is based on multivariable logistic regression for the primary outcome (death). The multivariable model adjusted for age
(> 65 years vs. ≤65 years), receipt of lung transplant hypertension, diabetes mellitus, heart failure, obesity, chronic kidney disease, coronary artery
disease, and chronic lung disease.

d

ICU admission status available for 551 patients in the early period and 388 patients in the late period.

e

Highest level of respiratory support and need for mechanical ventilation was available for 554 patients in the early period and 394 patients in the
late period. In the early period, eight patients who required mechanical ventilation also required extracorporeal membrane oxygenation (ECMO). In
the late period, two patients who required mechanical ventilation required ECMO.
f

Refers to initiation of renal replacement therapy among those who were not receiving renal replacement therapy prior to COVID-19 diagnosis (528
patients in the early period and 386 patients in the late period).

g

Infections include bacterial pneumonia, fungal pneumonia, and bloodstream infections. Only pathogen-proven infections were included. Some
patients experienced more than one infection.

h

Length of hospital stay was available for 547 patients in the early period and 391 patients in the late period. The number of days refer to the number
of days hospitalized during the first 28 days following Covid-19 diagnosis.

period when mortality was lower. Therefore, the observed decrease

improve oxygenation without mechanical ventilation, and overall

in mortality over time among SOTR hospitalized for COVID-19 also

adaptation of health care systems to the pandemic have been cited

does not appear to be fully explained by a shift towards lower base-

as potential reasons for lower contemporary mortality in the general

line illness severity in the later study period. Although we did not

population.4,5,7,18 The decrease in use of renal replacement therapy

collect data on all presenting features that have been associated

observed in this cohort is consistent with findings from the general

with death in COVID-19, abnormal chest imaging, lymphopenia, and

population and may reflect changes in the approach to volume man-

ICU admission are established predictors of mortality in COVID-19

agement over the course of the pandemic.19 We observed a decline

and likely correlated with other predictors of baseline disease sever-

in the use of mechanical ventilation, despite an increase in the pro-

ity, including baseline oxygen saturation.15–17 A higher proportion

portion of patients requiring any form of supplemental oxygen. The

of patients in the late period required some form of supplemental

observed decrease in mechanical ventilation likely reflects global

oxygen despite lower mortality in the late period, further suggesting

changes in the approach to the management of COVID-19 over

that the variations in disease severity do not explain the observed

time, as early intubation at the onset of hypoxemia was a frequent

decline in mortality.

practice early but became less common over time. 20 The current

Based on our findings of decreased mortality despite unchanged

observational study design does not allow for definitive testing of

surrogates of illness severity and controlling for baseline comorbidi-

these hypotheses and associations between specific interventions

ties between study periods, we speculate that general improvements

and outcomes should be interpreted with caution. Substantial con-

in care and COVID-specific treatments may explain the improved

founding by indication, whereby sicker patients were more likely to

survival in SOTR between the first and second portions of 2020.

receive therapeutic interventions, precludes meaningful assessment

The adoption of therapeutic corticosteroids, prone positioning to

of the association between various treatments and outcomes on
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TA B L E 3 Treatments for Covid-19 in solid organ transplant
recipients hospitalized for Covid-19 during early and late 2020
Early
period
(n = 571)

Treatment, n (%)

global pandemic. This practical study design did not allow for evaluation
of month-by-month variations in mortality. However, we defined study
periods using a logical cutoff time that corresponded with the timing

Late period
(n = 402)

p-value

a

demonstrate stable mortality throughout our study's later period.4 The

Corticosteroidsa

62 (10.9)

243 (61.4)

<.001*

Remdesivir

50 (8.8)

213 (53.0)

<.001*

Anti-IL−6/IL−6R agents

73 (12.8)

5 (1.2)

<.001*

the entire SOT population. We minimized the potential impact of report-

Hydroxychloroquine

329 (60.0)

4 (1.0)

<.001*

ing biases by limiting the analysis to patients hospitalized for COVID-19,

Convalescent plasma

48 (8.4)

119 (29.6)

<.001*

which created a more homogeneous study population. Although there

.07

were geographic differences between the two study periods, there was

Monoclonal antibodies
targeting
SARS-CoV−2
Any decrease in
maintenance of
immunosuppressionb
Hold antimetabolite

c

Decrease
antimetabolitec
Decrease CNI trough
goald

0 (0.0)

3 (0.8)

voluntary nature of participation and reporting of cases makes it challenging to understand the extent to which the study cohort represents

no difference in mortality across regions in the univariable analysis,
322 (79.1)

265 (65.9)

.05*

suggesting that any regional differences in care, including threshold for
hospitalization, were unlikely to explain the observed mortality trends.
There were significant differences in the racial and ethnic compo-

270 (66.5)

206 (65.8)

.87

51 (12.6)

31 (9.9)

.27

160 (30.3)

49 (13.3)

<.001*

Abbreviations: CNI, calcineurin inhibitor; CI, confidence interval; IL-6R,
interleukin-6 (IL-6), interleukin-6 receptor; OR, odds ratio.
a

p-values reflect χ2 and Fisher's exact tests for heterogeneity.
*Indicates statistical significance at α = .05.
b

of treatment paradigm shifts and data from the general population

Dosed at ≥6 mg dexamethasone equivalents per day.

c

Complete cessation or reduction in the dose or goal trough of at least
one maintenance immunosuppressive agent. Some patients had more
than one change. In the early period, corticosteroids were stopped in
2/438 (0.5%) patients taking steroids at baseline. In the late periods,
steroids were stopped in 1/277 (0.3%) and decreased in 1/277 (0.3%)
patients taking steroids at baseline.

d

Refers to percentage of patients taking and antimetabolite at the time
of Covid-19 diagnosis (406 patients in the early period and 313 patients
in the late period).

e

Refers to percentage of patients taking a calcineurin inhibitor at
baseline (528 patients in the early period and 368 patients in the late
period).
f

Refers to percentage of patients taking a corticosteroid at baseline
(438 patients in the early period and 277 patients in the late period).
Corticosteroid dose was decreased in one patient in the late period; all
other steroid decrease involved complete cessation.

sition of patients between time periods. Social determinants of health
and structural racism have placed racial and ethnic minority groups at
a higher risk for SARS-CoV-2 acquisition as well as the medical comorbidities that are associated with poor outcomes from COVID-19.21–23
As such, Black and Hispanic or Latinx patients account for a disproportionately high percentage of COVID-19 cases and deaths, and mortality
among waitlisted Black kidney transplant candidates increased disproportionately after the start of the COVID-19 pandemic.23-25 However,
among all patients who are hospitalized for COVID-19, neither racial
nor ethnic minority status has been independently associated with an
increased risk of death, and comorbidity-adjusted analyses suggest
that hospitalized Black and Hispanic or Latinx patients with COVID-19
may be less likely to die than non-Hispanic White patients.24,26,27
These observations support the definition of race and ethnicity as
social constructs that reflect risk factors for COVID-19 exposure and
underlying comorbidities without independent biological implications
for disease progression following infection.28 In our cohort of SOT
recipients hospitalized for COVID-19, neither race nor ethnicity were
associated with death. Therefore, it is unlikely that the temporal variation in the racial and ethnic composition of our cohort is related to the
observed trends in mortality.
In conclusion, this large multicenter study demonstrates that
mortality among hospitalized SOTR with COVID-19 decreased over
the course of the pandemic, reflecting trends observed in the general population. These data provide indirect evidence of a benefit of

the individual level. Thus, our data provide only indirect evidence

advances in care and COVID-19 therapies in the general population

that contemporary management of COVID-19 may similarly benefit

to SOTR. Future studies to define the mechanism(s) and their rela-

SOTR and the general population.

tive contributions to improvements in short-term survival in SOTR

The strengths of this study include the relatively large sample size,

hospitalized for COVID-19 are warranted.

institutional and geographic diversity, standardized data collection and
follow-up, and inclusion of cases of COVID-19 diagnosed throughout

AC K N OW L E D G M E N T S

the entire course of the year 2020. Nonetheless, there are several
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servational design leading to inability to detect the impact of specific in-
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Sait MD, Amy Rumore PharmD, Patricia West PhD, Amy Jeng MD,
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